Marken Launches Exclusive Shipping System for Specimen Logistics
Marken announced the launch of its new BioSystem shipping system, designed specifically for biological samples, to further enhance its global biological logistics services. Marken has leveraged its extensive global experience in clinical specimens transport and has designed a system with technology for prolonged temperature control while also standardizing box size for optimum freight costs and dry ice use. Marken will deploy these new systems, together wits already proven logistics management style, across their global network of 24 locations which currently support over 49,000 investigators in more than 150 countries.
The Marken BioSystem is designed to assure product integrity throughout the temperature controlled chain in three standard sizes: 5Kgs, 9Kgs and 15Kgs volumetric weight. Each size is rated to keep biological products frozen for 72 hours or more. The systems have been engineered to be environmentally friendly, validated to conform to ISTA 7E enhanced protocol and are regionally IATA PI620 approved for the transport of biological specimens.
Additionally, the new boxes are expected to reduce greenhouse emissions by up to 40% with a decreased carbon footprint from the reduction of styrene, cardboard and use of less dry ice to achieve greater performance at the same cost as conventional solutions.
The BioSystem series is a first of its kind. It will be globally available. It will allow for universal standardization in all clinical protocols and will support all regions with one consistent application. Clinical researchers will soon have a single global solution to transport specimens using consistent packaging and services from the most remote sites in Europe, Asia, Middle East and the Americas.
The new BioSystem packaging is the latest enhancement to Marken’s global clinical trials support services which includes GMP storage conditions, 24/7/365 proactive temperature management, active monitoring throughout the cold chain, packaging collection and recycling. Marken also offers onsite training and regulatory consulting for all countries.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
